Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Vaxcyte, Inc. (PCVX : NSDQ)
 
 • Company Description   
Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.

Number of Employees: 414

 
 • Price / Volume Information   
Yesterday's Closing Price: $31.16 Daily Weekly Monthly
20 Day Moving Average: 2,037,938 shares
Shares Outstanding: 129.00 (millions)
Market Capitalization: $4,019.77 (millions)
Beta: 1.27
52 Week High: $121.06
52 Week Low: $27.66
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.13% -5.36%
12 Week -62.90% -59.92%
Year To Date -61.94% -60.44%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
825 INDUSTRIAL ROAD STE. 300
-
SAN CARLOS,CA 94070
USA
ph: 650-837-0111
fax: -
investors@vaxcyte.com https://vaxcyte.com
 
 • General Corporate Information   
Officers
Grant E. Pickering - Chief Executive Officer and Director
Andrew Guggenhime - President and Chief Financial Officer
Elvia Cowan - Senior Vice President and Finance
Carlos Paya - Director
Annie Drapeau - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92243G108
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 129.00
Most Recent Split Date: (:1)
Beta: 1.27
Market Capitalization: $4,019.77 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.10 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.65 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 3.26% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.26
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -22.35%
vs. Previous Quarter: -1.96%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/25 - -17.12
12/31/24 - -17.35
09/30/24 - -23.53
ROA
03/31/25 - -16.26
12/31/24 - -16.50
09/30/24 - -22.20
Current Ratio
03/31/25 - 17.70
12/31/24 - 12.76
09/30/24 - 17.88
Quick Ratio
03/31/25 - 17.70
12/31/24 - 12.75
09/30/24 - 17.88
Operating Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Net Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Pre-Tax Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Book Value
03/31/25 - 24.81
12/31/24 - 26.52
09/30/24 - 30.62
Inventory Turnover
03/31/25 - -
12/31/24 - -
09/30/24 - -
Debt-to-Equity
03/31/25 - 0.00
12/31/24 - 0.00
09/30/24 - 0.00
Debt-to-Capital
03/31/25 - 0.00
12/31/24 - 0.00
09/30/24 - 0.00
 

Powered by Zacks Investment Research ©